✨ Unlock Unlimited Data Exports & Disclosures Access with Tracenable Pro. Learn More →

Vertex Pharmaceuticals Inc

Common Name
Vertex Pharmaceuticals
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
6,100
Ticker
VRTX
Exchange
NASDAQ/NGS
Description
Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of innovative therapies for serious diseases. Primarily, Vertex is known for...

Vertex Pharmaceuticals's GHG Emissions Data Preview

In 2024, Vertex Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

However, Vertex Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Location-Based
Copy/Paste is a PRO feature.
0000000
Copy/Paste is a PRO feature.
c
0000000
Total Scope 3
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Vertex Pharmaceuticals’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2019, and revenue-based intensity metrics for each scope.
Unrestricted Access to Data and Sources
pro
Remove manual data sourcing from your workflow. Upgrade to Tracenable Pro for unrestricted access to datasets and disclosures across 8,500+ companies with over 10 years of historical coverage.
Download complete datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace values back to original sources
Formats Included
Excel
CSV
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=VRTX&reporting_period=2024"

Verified Sources Behind Vertex Pharmaceuticals’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Vertex Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.

a. Vertex Pharmaceuticals's Corporate Responsibility Report (CRR) 2024
b. Vertex Pharmaceuticals's Corporate Responsibility Report (CRR) 2023
c. Vertex Pharmaceuticals's Financial & Extra-Financial Disclosure 2022
d. Vertex Pharmaceuticals's Corporate Responsibility Report (CRR) 2021

Insights into Vertex Pharmaceuticals's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals amounted to 12,906 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Vertex Pharmaceuticals decreased by 43.19%, showing that the company has made progress in taking action to reduce the climate impact of its operations.ab

Vertex Pharmaceuticals's Scope 1 Emissions Over Time

20192020202120222023202402.5 k5 k7.5 k10 ktCO2e-3%+9%+52%-11%+8%
  • Total Scope 1
  • Year-over-Year Change

What are Vertex Pharmaceuticals's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Vertex Pharmaceuticals were 8,976 metric tons of CO₂ equivalent (tCO₂e).a

Has Vertex Pharmaceuticals reduced its Scope 1 emissions over time?

Since 2019, Vertex Pharmaceuticals's Scope 1 emissions have increased by 53.86%, reflecting a rising long-term trend in Scope 1 emissions over time.ad

Compared to the previous year (2023), Vertex Pharmaceuticals's Scope 1 emissions increased by 8%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Vertex Pharmaceuticals's Scope 2 emissions?

In 2024, Vertex Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 3,930 tCO₂e using the market-based method.a

Has Vertex Pharmaceuticals reduced its Scope 2 emissions over time?

Since 2019, Vertex Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 50.83%, reflecting a declining long-term trend in Scope 2 emissions over time.ad

What methodology does Vertex Pharmaceuticals use for Scope 2 reporting?

In 2024, Vertex Pharmaceuticals reported its Scope 2 emissions using the market-based method.a

Vertex Pharmaceuticals's Scope 2 Emissions Over Time

20192020202120222023202404 k8 k12 k16 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Vertex Pharmaceuticals's Value Chain Emissions

In 2024, Vertex Pharmaceuticals reported 551,647 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Vertex Pharmaceuticals includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Vertex Pharmaceuticals's Scope 3 Emissions Over Time

20202022202320240150 k300 k450 k600 ktCO2e+21%+90%+16%
  • Total Scope 3
  • Year-over-Year Change

What are Vertex Pharmaceuticals's Scope 3 emissions?

In 2024, Vertex Pharmaceuticals reported total Scope 3 emissions of 551,647 metric tons of CO₂ equivalent (tCO₂e).a

Compared to the previous year (2023), Vertex Pharmaceuticals's Scope 3 emissions increased by 16.35%, suggesting that the company faced challenges in reducing emissions across its value chain.a

Insights into Vertex Pharmaceuticals’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Vertex Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 8,976 tCO₂e and total revenues of USD 11,020 millions. This translates into an emissions intensity of 0.81 tCO₂e per millions USD.a

Vertex Pharmaceuticals's Scope 1 Emissions Intensity Compared to Peers

2501,00020,000500,000Scope 1 Emissions (tCO2e)101005005,00050,000Revenues (Millions of USD)FSCIncyteYear: 2024Scope 1: 9,576 tCO2eRevenue: $M 4,241Scope 1 Intensity: 2.26 tCO2e/$MBio-TechneYear: 2023Scope 1: 3,001 tCO2eRevenue: $M 1,137Scope 1 Intensity: 2.64 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MLegend BiotechYear: 2024Scope 1: 769 tCO2eRevenue: $M 627Scope 1 Intensity: 1.23 tCO2e/$MFFFortrea HoldingsYear: 2023Scope 1: 864 tCO2eRevenue: $M 3,109Scope 1 Intensity: 0.28 tCO2e/$MFrontage HoldingsYear: 2023Scope 1: 2,883 tCO2eRevenue: $M 2,027Scope 1 Intensity: 1.42 tCO2e/$MEdwards LifesciencesYear: 2024Scope 1: 15,682 tCO2eRevenue: $M 5,439Scope 1 Intensity: 2.88 tCO2e/$MRegeneron PharmaceuticalsYear: 2024Scope 1: 80,300 tCO2eRevenue: $M 14,202Scope 1 Intensity: 5.65 tCO2e/$MHalozyme TherapeuticsYear: 2024Scope 1: 1,348 tCO2eRevenue: $M 1,015Scope 1 Intensity: 1.33 tCO2e/$MZoetisYear: 2024Scope 1: 101,392 tCO2eRevenue: $M 9,256Scope 1 Intensity: 10.95 tCO2e/$MModernaYear: 2024Scope 1: 13,180 tCO2eRevenue: $M 3,199Scope 1 Intensity: 4.12 tCO2e/$MSarepta TherapeuticsYear: 2023Scope 1: 3,428 tCO2eRevenue: $M 1,243Scope 1 Intensity: 2.76 tCO2e/$MCharles River LaboratoriesYear: 2023Scope 1: 85,723 tCO2eRevenue: $M 4,129Scope 1 Intensity: 20.76 tCO2e/$MSSSolventumYear: 2024Scope 1: 146,000 tCO2eRevenue: $M 8,254Scope 1 Intensity: 17.69 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MZimmer Biomet HoldingsYear: 2024Scope 1: 10,191 tCO2eRevenue: $M 7,679Scope 1 Intensity: 1.33 tCO2e/$MIDEXX LaboratoriesYear: 2024Scope 1: 18,461 tCO2eRevenue: $M 3,898Scope 1 Intensity: 4.74 tCO2e/$MCCCatalyst PharmaceuticalsYear: 2024Scope 1: 4 tCO2eRevenue: $M 493Scope 1 Intensity: 0.01 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MIntuitive SurgicalYear: 2024Scope 1: 8,105 tCO2eRevenue: $M 8,352Scope 1 Intensity: 0.97 tCO2e/$MIonis PharmaceuticalsYear: 2024Scope 1: 2,616 tCO2eRevenue: $M 705Scope 1 Intensity: 3.71 tCO2e/$MVertex PharmaceuticalsYear: 2024Scope 1: 8,976 tCO2eRevenue: $M 11,020Scope 1 Intensity: 0.81 tCO2e/$M

How does Vertex Pharmaceuticals's GHG emissions intensity compare to its peers?

In 2024, Vertex Pharmaceuticals reported a Scope 1 emissions intensity of 0.81 tCO₂e per millions USD. Compared to the peer group median of 2.82, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Vertex Pharmaceuticals rank on GHG emissions intensity within its industry?

In 2024, Vertex Pharmaceuticals ranked 3 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Vertex Pharmaceuticals among the top performers, with one of the lowest emissions intensities relative to peers.a

Insights into Vertex Pharmaceuticals's Total Carbon Footprint

In 2024, Vertex Pharmaceuticals reported a total carbon footprint of 564,553 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 13.63% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.ab

The largest contributor to Vertex Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 97.71% of the company's total carbon footprint, followed by Scope 1 emissions at 1.59%.a

Want Full Access to Vertex Pharmaceuticals's GHG Emissions Dataset?
Sign Up